| 11/26/07 | Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9 |
| 11/12/07 | Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting |
| 11/09/07 | Dynavax to Present at Credit Suisse 2007 Healthcare Conference |
| 11/01/07 | Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences |
| 11/01/07 | Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 |
| 11/01/07 | Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook |
| 10/22/07 | Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study |
| 09/19/07 | Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial |
| 09/18/07 | Dynavax to Present at UBS 2007 Global Life Sciences Conference |
| 09/06/07 | Dynavax to Present at Bear Stearns 20th Annual Healthcare Conference |
| 08/16/07 | Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists |
| 08/07/07 | Dynavax Awarded $3+ Million Universal Flu Vaccine Grant from NIAID |
| 07/31/07 | Dynavax Announces Second Quarter 2007 Financial Results |
| 07/18/07 | Dynavax Receives $30 Million Commitment by Deerfield Management for TLR9 Allergy Franchise |
| 07/12/07 | Dynavax Completes Enrollment of HEPLISAV(TM) Phase 3 |
| 06/26/07 | Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada |
| 06/11/07 | Dynavax to Present at the Sixth Annual Needham Biotechnology & Medical Technology Conference |
| 06/04/07 | Dynavax to Present at the Third Annual Bear Stearns Biotech Confab |
| 05/29/07 | Dynavax to Present at the Bank of America 2007 Health Care Conference |
| 05/02/07 | Dynavax Announces First Quarter 2007 Financial Results |
| 04/06/07 | Dynavax to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
| 03/13/07 | Dynavax to Present at Cowen and Company Health Care Conference |
| 03/01/07 | Dynavax Initiates Phase I Trial of Hepatitis B Therapy |
| 02/23/07 | Dynavax Provides 2007 Financial Outlook |
| 02/23/07 | Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI |
| 02/22/07 | Dynavax Announces Webcast on AAAAI Data and 2007 Financial Outlook |
| 02/13/07 | Dynavax Announces Fourth Quarter and Year End 2006 Financial Results |
| 01/08/07 | Dynavax Reports Interim TOLAMBA(TM) Ragweed Allergy Results From DARTT Trial |
| 12/20/06 | Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine |
| 12/12/06 | Dynavax Appoints Dr. David M. Lawrence, Kaiser Chairman Emeritus, to Board of Directors |
| 12/10/06 | Dynavax Reports Positive Phase 2a NHL Data at ASH Meeting |
| 12/05/06 | Dynavax Initiates Phase 1 Clinical Trial in Metastatic Colorectal Cancer |
| 12/04/06 | Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows 100% Seroprotection Regardless of Vaccination Schedule in Phase 2 Trial |
| 11/28/06 | Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial |
| 11/12/06 | Dynavax Reports New TOLAMBA Data at ACAAI Meeting |
| 10/31/06 | Dynavax Technologies Names Michael Ostrach VP, Chief Business Officer and General Counsel |
| 10/26/06 | Dynavax Announces Third Quarter 2006 Financial Results and Updates 2006 Financial Guidance |
| 10/20/06 | Dynavax Announces Third Quarter 2006 Financial Results Conference Call and Webcast |
| 10/19/06 | Dynavax's Universal Flu Vaccine Improves Response of Standard Flu Vaccines |
| 10/10/06 | Dynavax Announces Closing of Common Stock Offering and Exercise of Underwriter's Over-Allotment Option |
| 10/04/06 | NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial |
| 10/04/06 | Dynavax Raises $27 Million in Common Stock Offering |
| 09/21/06 | Dynavax to Present at UBS Global Life Sciences Conference |
| 09/06/06 | Dynavax Establishes Collaboration for TLR-9 Agonists for Asthma and COPD With AstraZeneca |
| 08/31/06 | Dynavax Secures Equity Financing Commitment of Up to $30 Million |
| 08/21/06 | Dynavax's Flu Vaccine Shows Immunity to Divergent and Potentially Pandemic Flu Strains in Preclinical Tests |
| 08/16/06 | Dynavax Appoints Peggy V. Phillips to Board of Directors |
| 07/27/06 | Dynavax Announces Second Quarter 2006 Financial Results |
| 07/13/06 | Dynavax Announces Second Quarter 2006 Financial Results Conference Call and Webcast |
| 06/07/06 | Dynavax Announces Completion of Enrollment in TOLAMBA(TM) Ragweed Allergy Trial |
| 06/05/06 | Dynavax to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference |
| 05/24/06 | Dynavax to Present at Friedman Billings Ramsey 2006 Growth Investor Conference |
| 05/04/06 | Dynavax Scientist Receives 'European Inventor of the Year' Award From European Patent Office for Vaccine Production Platform |
| 04/27/06 | Dynavax Announces First Quarter 2006 Financial Results and Outlook |
| 04/26/06 | Dynavax Chief Scientific Officer, Robert L. Coffman, Ph.D., Elected to National Academy of Sciences |
| 04/25/06 | Dynavax to Present at Deutsche Bank Securities 31st Annual Healthcare Conference |
| 04/24/06 | Dynavax Closes Acquisition of Rhein Biotech GmbH From Crucell |
| 04/20/06 | Dynavax Announces First Quarter 2006 Financial Results Conference Call and Webcast |
| 04/19/06 | Dynavax to Advance Cancer, Hepatitis B and Hepatitis C Therapy Programs With $50 Million Funding |
| 03/30/06 | Dynavax to Present at CIBC Annual Biotechnology & Specialty Pharmaceutical Conference |
| 03/27/06 | Dynavax to Acquire Rhein Biotech GmbH From Crucell |
| 03/20/06 | Dynavax to Present at Bear Stearns Biotech West Coast Confab |
| 03/15/06 | Dynavax Announces Fourth Quarter and Year-End 2005 Financial Results |
| 03/06/06 | Dynavax Presents Positive TOLAMBA Phase 2/3 Results at AAAAI Meeting |
| 03/02/06 | Dynavax Announces Fourth Quarter 2005 Financial Results Conference Call and Webcast |
| 03/01/06 | Dynavax Provides Update on TOLAMBA Program |
| 02/23/06 | Dynavax Announces Board of Directors Changes |
| 02/15/06 | Dynavax to Present Data on Phase 2/3 Clinical Trial of TOLAMBA at AAAAI 2006 |
| 02/08/06 | Dynavax to Present at Two Focus Sessions at BIO CEO & Investor Conference February 15, 2006 |
| 01/24/06 | Dynavax to Participate in Webcast Hosted by Pacific Growth Equities, LLC |
| 01/18/06 | Dynavax's Ragweed Allergy Therapy, TOLAMBA(TM), Achieves Primary Efficacy and Safety Endpoints in Phase 2/3 Trial |
| 12/19/05 | Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial |
| 12/07/05 | Dynavax to Present Data on Phase 2/3 Clinical Trial of HEPLISAV(TM) Hepatitis B Vaccine at ICAAC 2005 |
| 11/10/05 | Dynavax Announces Exercise of Underwriters' Over-Allotment Option |
| 11/07/05 | Dynavax's TOLAMBA(TM) Demonstrates Safety in Phase 1 Trial of Ragweed Allergic Children |
| 11/02/05 | Dynavax Appoints Nancy L. Buc, Former FDA Chief Counsel, to its Board of Directors |
| 11/01/05 | Dynavax Initiates US-Based Phase 1 Clinical Trial of HEPLISAV(TM) Hepatitis B Vaccine in Dialysis Population |
| 10/27/05 | Dynavax Announces Third Quarter 2005 Financial Results |
| 10/25/05 | Dynavax to Webcast Presentations at Upcoming Healthcare Conferences |
| 10/19/05 | Dynavax Announces Third Quarter 2005 Financial Results Conference Call and Webcast |
| 10/14/05 | Dynavax Announces Closing of Common Stock Offering Under Shelf Registration Statement |
| 10/11/05 | Dynavax Announces Pricing of Public Offering of Common Stock Under Shelf Registration Statement |
| 10/03/05 | Dynavax Announces Proposed Public Offering of Common Stock Under Shelf Registration Statement |
| 09/27/05 | Dynavax Introduces TOLAMBA(TM) and HEPLISAV(TM) Brand Names for Ragweed Allergy and Hepatitis B Vaccine Products |
| 08/31/05 | Dynavax to Webcast Presentation at Bear Stearns 18th Annual Healthcare Conference |
| 08/29/05 | Dynavax Files Shelf Registration Statement |
| 08/17/05 | Dynavax Appoints Accalimed Vaccine Pioneer Dr. Stanley A. Plotkin to Board of Directors |
| 07/28/05 | Dynavax Technologies Second Quarter 2005 Earnings Conference Call |
| 07/28/05 | Dynavax Announces Second Quarter 2005 Financial Results |
| 07/14/05 | Dynavax Technologies Second Quarter 2005 Earnings Conference Call |
| 07/14/05 | Dynavax Announces Second Quarter 2005 Financial Results Conference Call and Webcast |
| 07/11/05 | Dynavax Announces Rapid, Expanded Enrollment in Ragweed Allergy Pediatric Trial |
| 06/23/05 | Dynavax Initiates Pivotal Phase 3 Trial for Hepatitis B Vaccine |
| 06/14/05 | Dynavax Announces Positive Primary Endpoint Results From Phase 2/3 Hepatitis B Vaccine Trial |
| 05/25/05 | Dynavax to Webcast Presentation at Pacific Growth Equities 2005 Life Sciences Conference |
| 05/23/05 | Dynavax to Webcast Presentation at Friedman Billings Ramsey Conference |
| 05/09/05 | Dynavax Flu Vaccine Shows Potential Against Pandemic Flu in Preclinical Model |
| 04/28/05 | Dynavax Announces First Quarter 2005 Financial Results |
| 04/21/05 | Dynavax to Webcast Presentation at Deutsche Bank Healthcare Conference, May 3, 2005 |
| 04/20/05 | Dynavax Technologies Announces First Quarter 2005 Earnings Conference Call |
| 04/20/05 | Dynavax Announces First Quarter 2005 Financial Results Conference Call and Webcast |
| 03/29/05 | Dynavax to Webcast Presentation at Future Leaders in the Biotech Industry Conference, April 7, 2005 |
| 03/21/05 | Dynavax Anthrax Vaccine Induces High Antibody Responses and Shows Protection in Preclinical Model |
| 03/21/05 | Positive Single-Season Phase 1 Data on Dynavax's AIC Ragweed Allergy Therapy Presented at AAAAI Meeting |
| 03/18/05 | Dynavax Regains Rights to Seasonal Allergy Program From UCB |
| 02/17/05 | Dynavax to Present at BIO CEO & Investor Conference February 24, 2005 |
| 02/15/05 | Dynavax Announces Fourth Quarter and Year-End 2004 Financial Results and 2005 Outlook |
| 02/08/05 | Dynavax Announces Fourth Quarter and Year-End 2004 Financial Results and Outlook |
| 02/07/05 | Dynavax Announces February 15, 2005 Webcast of Fourth Quarter and Year-End 2004 Financial Results and Outlook |
| 01/18/05 | Dynavax to Webcast Presentation at Piper Jaffray Health Care Conference on Tuesday, January 25, 2005 |
| 01/10/05 | Dynavax Debuts Novel IRS Technology: New Platform for Autoimmune Disease Drug Discovery |
| 01/05/05 | Dynavax Appoints Deborah A. Smeltzer as Chief Financial Officer |
| 12/20/04 | Dynavax Announces Interim Analysis From Ragweed Allergy Phase 2/3 Trial |
| 12/09/04 | Dynavax Announces Positive Interim Results From Phase 2/3 Hepatitis B Vaccine Trial |
| 11/15/04 | Dynavax Peanut Immunotherapy Inhibits Allergic Response in Preclinical Studies |
| 11/08/04 | Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast |
| 11/08/04 | Dynavax Announces Third Quarter 2004 Financial Results |
| 11/01/04 | Dynavax's Hepatitis B Vaccine Shows More Rapid Immunogenicity, More Durable Protective Response Than Engerix-B in Phase 2 Clinical Trial |
| 10/27/04 | Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast |
| 10/20/04 | Dynavax to Present Data on Phase 2 Clinical Trial of Hepatitis B Vaccine at ICAAC |
| 10/18/04 | Dynavax Establishes Collaboration With Riken Institute for Development of Cedar Allergy Therapeutics for Japanese Market |
| 09/27/04 | Dynavax to Webcast Presentation at UBS Global Life Sciences Conference on Thursday, September 30, 2004 |
| 09/27/04 | Dynavax Appoints Jane Green Vice President, Corporate Communications |
| 09/02/04 | Dynavax Announces Completion of Enrollment of Phase II/III Hepatitis B Prophylactic Vaccine Trial |
| 08/24/04 | Dynavax Names Timothy Henn, Vice President, Finance & Administration |
| 08/05/04 | Dynavax Reports 2004 Second Quarter Results |
| 07/28/04 | Dynavax Asthma Data Supports Advancing Program to Efficacy Trials |
| 06/24/04 | Dynavax Completes Phase I Immunization in Pediatric Ragweed Allergy Trial |
| 06/22/04 | Dynavax Announces Initiation of Phase II/III Hepatitis B Trial |
| 06/07/04 | Dynavax to Webcast Annual Meeting |
| 05/20/04 | Dynavax Announces CFO to Step Down |
| 05/19/04 | Dynavax Announces Full Enrollment of Phase II/III AIC Trial |
| 05/04/04 | Dynavax Reports 2004 First Quarter Results |
| 03/29/04 | /C O R R E C T I O N -- Dynavax Technologies Corporation/ |
| 03/29/04 | Dynavax Reports 2003 Fourth Quarter and Full Year Results |
| 03/25/04 | Dynavax Full Year and Fourth Quarter Earnings Conference Call |
| 03/08/04 | Dynavax Names Denise M. Gilbert to Board of Directors |
| 03/04/04 | Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer |
| 02/25/04 | Dynavax Initiates Phase II/III Clinical Trial for Ragweed
Allergy Immunotherapy |
| 02/24/04 | Dynavax Announces Exercise of Underwriters' Over-Allotment Option |
| 02/19/04 | Dynavax Prices IPO at $7.50 Per Share |
| 02/05/04 | Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products |
| 12/18/03 | Dynavax Announces USPTO Declaration of Interference to Resolve Inventorship of ISS Intelectual Property |
| 11/03/03 | Dynavax Technologies and Berna Biotech Announce Collaboration |
| 10/24/03 | Dynavax Technologies Corporation Files Registration Statement for Initial Public Offering |
| 08/04/03 | Dynavax Names Daniel Levitt Vice President and Chief Medical Officer |
| 09/04/02 | Dynavax Initiates Phase II Clinical Trial of ISS Vacine for Hepatitis B - Study Focuses on Single-Injection Approach |
| 08/22/02 | Dynavax Names William J. Dawson Vice President, Finance and Operations, and Chief Financial Officer |
| 04/25/02 | Dynavax Raises $34.8 Million In Private Equity Round Led By Care Capital |
| 12/06/00 | Dynavax Names New Vice Presidents |
